News & Events
Take a look at our most recent news and upcoming events below.
News
Rifapentine Shortage
The U.S. Food and Drug Administration (FDA) Releases Report: National Shortage of Rifapentine Tablets
The Year in TB: 2019
2019 Annual Tuberculosis Statistics. With World TB Day on March 24, find out the state and national numbers here!
New Guidelines for Treatment of Latent TB Infection
The U.S. Centers for Disease Control and Prevention (CDC) and the National Tuberculosis Controllers Association (NTCA) Release New Guidelines for Treatment of Latent Tuberculosis Infection (LTBI).
APLISOL® Inventory Replenished
FDA has removed Aplisol from its current shortage listing.
Updated Recommendations for TB Testing and Treatment for Health Care Personnel
The Centers for Disease Control and Prevention (CDC) and the National Tuberculosis Controllers Association (NTCA) have released “Tuberculosis Screening, Testing, and Treatment of U.S. Health-Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019”
Revised 2018 Follow up Worksheet and needs for Ohio Disease Reporting System (ODRS)
Revised 2018 Follow up Worksheet and needs for Ohio Disease Reporting System (ODRS) - Video training with visuals (25:59). Discusses changes to Electronic Disease Notification (EDN) Follow-Up Worksheet and changes in entry into Immigrant Investigation cases in ODRS.
CDC HEALTH ADVISORY: Nationwide Shortage of Tuberculin Skin Test Antigens
Nationwide Shortage of Tuberculin Skin Test Antigens: CDC Recommendations for Patient Care and Public Health Practice
2018 Annual TB Report Now Available
Ohio's Tuberculosis Data for 2018 is now available.
Interruption in the Supply of Cycloserine
12/10/2018: The Centers for Disease Control and Prevention (CDC) has learned of an interruption in the supply of cycloserine, which is likely to last for at least the next several weeks.
Provider Resource - Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat LTBI
National TB Controllers Association's (NTCA) new resource for providers regarding the isoniazid-rifapentine (3HP) regimen to Treat latent tuberculosis infection (LTBI) based on the Centers for Disease Control and Prevention's (CDC) recently released guidance.